InvestorsHub Logo
Followers 87
Posts 6641
Boards Moderated 1
Alias Born 09/18/2009

Re: cowtown jay post# 42114

Wednesday, 05/29/2024 9:27:23 PM

Wednesday, May 29, 2024 9:27:23 PM

Post# of 42746
"Research into Disease X also requires gain-of-function utilization, to possibly produce another novel coronavirus, which I think could be the Pangolin Coronavirus GX_P2V..."

More recent discussion suggests that "Disease X" could actually prove to be a version of H5N1 bird flu, which could be, or will become, genetically modified. Dr. Kelly Victory, one of my favorites, conducted an excellent interview of Dr. Brian Hooker, PhD, on this subject of "H5N1 Bird Flu: New Pandemic Gets New mRNA Vaccine," starting at minute marker 09:30 in the following video.



However, I don't think this is necessarily going to be a lather-rinse-repeat of what we have seen in the programmed governmental response to covid.

I'm glad to see that Sanofi acknowledged their co-exclusive licensing agreement with Novavax yesterday.

https://www.sec.gov/Archives/edgar/data/1121404/000119312524147826/d839421d6k.htm

I was hoping that we would finally hear from Humanigen/Taran that lenz is the product being licensed to Sanofi and Novavax for their covid and covid/flu vaccines. For that matter, I'd like to see that Gracell and Mayo Clinic may also announce co-exclusive licensing of lenz for their CAR-T platforms.

The point is, that while regulators will likely continue to push for mRNA vaccines for their sponsors' covid/flu products, trials are underway for Novavax/Sanofi to use traditional vaccine technology, hopefully enhanced by lenz.

Billions of covid revenue dollars are at stake for Humanigen/Taran, along with Sanofi and Novavax. I think management has captured that opportunity for us. I think we should know by the 13th, perhaps earlier if the Liquidating Trust is dissolved.